Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: Comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies

Table 1 Baseline characteristics of donor-specific antibodies-Cw and donor-specific antibodies-A-B groups

	DSA-A-Bn = 23	DSA-Cwn = 12	P
Recipient
Age (yr), median (IQR)	48 (39-55)	39 (33-49)	0.061
Female gender, n (%)	13 (57)	6 (50)	0.713
Retransplant, n (%)	11 (48)	5 (42)	0.728
Previous blood transfusions, n (%)	9 (39)	9 (75)	0.044
Previous pregnancies, n (%)	8 (35)	8 (33)	1
Kidney-pancreas transplantation, n (%)	1 (4)	1 (8)	1
Donor
Age (yr), median (IQR)	45 (36-56)	45 (32-54)	0.542
Female gender, n (%)	8 (35)	8 (33)	1
Living donor, n (%)	1 (4)	2 (17)	0.266
Pretransplant immunological data
Peak PRA, median (IQR)	4 (0-80)	8 (0-52)	0.472
DSA number, median (range)	1 (1-3)	1 (1-2)	0.056
DSAsum MFI, median (IQR)	7583 (2320-12395)	2939 (2529-3650)	0.11
Transplant
ABDR HLA mismatches, mean ± SD	3.22 ± 1.28	4.08 ± 1.16	0.056
FCXM-T + (n = 29), n (%)	1 (6)	3 (27)	0.139
FCXM-B + (n = 29), n (%)	2 (11)	0	0.512
ATG induction, n (%)	14 (61)	9 (75)	0.476
Tacrolimus (vs CsA), n (%)	20 (87)	12 (100)	0.536
Desensitized, n (%)	5 (22)	3 (25)	1
IvIg only, n	2	3
IvIg + PP, n	1	0
IvIg + Rtx + PP, n	2	0

DSA: Donor-specific antibodies; MFI: Mean fluorescence intensity; IQR: Interquartile range; SD: Standard deviation; CKD: Chronic kidney disease; PRA: Panel reactive antibodies; HCV: Hepatitis C virus; CMV: Cytomegalovirus; HLA: Human leukocyte antigen; ATG: Anti-thymocyte globulin; CsA: Cyclosporin; IvIg: Intravenous immunoglobulin; PP: Plasmapheresis; Rtx: Rituximab.